Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.07 +0.25%
EPS Growth %: -70.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -70.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
- BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
